Previous close | 0.7260 |
Open | 0.7400 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.7010 - 0.7400 |
52-week range | 0.6520 - 11.9100 |
Volume | |
Avg. volume | 55,835 |
Market cap | 4.941M |
Beta (5Y monthly) | 0.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ATLANTA, December 11, 2023--Alzamend Neuro Receives FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug to Treat PTSD
ATLANTA, November 20, 2023--Alzamend Gets FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001 a Next-Generation Lithium Therapeutic for Major Depressive Disorder
ATLANTA, November 16, 2023--Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement